title: [Thromboangiitis obliterans (Buerger's disease): update 2015].
abstract: Thromboangiitis obliterans (Buerger's disease) is a vasculitis with undulating clinical course multisegmentarily affecting small and medium-sized arteries and veins. The disease is closely linked to tobacco-use. Increasing knowledge of autoimmunologic mechanisms in the complex pathophyiology of the disease let to the formulation of an autoimmunity-hypothesis now serving as a new paradigma. New treatment options comprise progenitor-cell-therapy, immunoadsorption, use of sendothelin-receptor-blocking agent Bosentan, and prescriptions of antiphosphodiesterase-V-inhibitors.
authors.affiliation: Klinik für Angiologie, HELIOS Klinikum Berlin-Buch, Berlin.
authors.forename: Peter
authors.initials: P
authors.lastname: Klein-Weigel
authors.affiliation: Klinik für Angiologie, HELIOS Klinikum Berlin-Buch, Berlin.
authors.forename: Theresa Sophie
authors.initials: TS
authors.lastname: Volz
authors.affiliation: Poliklinik, Funktionsbereich & Hiller Forschungszentrum für Rheumatologie, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität, Düsseldorf.
authors.forename: Jutta
authors.initials: J
authors.lastname: Richter
mesh_terms: D000077300:Bosentan; D065128:Endothelin Receptor Antagonists; D019317:Evidence-Based Medicine; D006801:Humans; D007163:Immunosorbent Techniques; D033581:Stem Cell Transplantation; D013449:Sulfonamides / Q000627:therapeutic use*; D013919:Thromboangiitis Obliterans / Q000175:diagnosis* / Q000276:immunology / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D065128:Endothelin Receptor Antagonists; D013449:Sulfonamides; D000077300:Bosentan